Last reviewed · How we verify

Flublok Quadrivalent Influenza Vaccine

Protein Sciences Corporation · Phase 3 active Biologic

Flublok Quadrivalent Influenza Vaccine is a Recombinant protein vaccine Biologic drug developed by Protein Sciences Corporation. It is currently in Phase 3 development for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older.

Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells.

Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells. Used for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older.

At a glance

Generic nameFlublok Quadrivalent Influenza Vaccine
SponsorProtein Sciences Corporation
Drug classRecombinant protein vaccine
TargetInfluenza hemagglutinin (HA) antigen
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

This vaccine uses recombinant DNA technology to produce hemagglutinin proteins from four influenza strains (two A subtypes and two B lineages) in cultured insect cells, rather than growing virus in eggs. The recombinant hemagglutinin antigens trigger both humoral and cellular immune responses, generating antibodies and T-cell immunity against the targeted influenza strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Flublok Quadrivalent Influenza Vaccine

What is Flublok Quadrivalent Influenza Vaccine?

Flublok Quadrivalent Influenza Vaccine is a Recombinant protein vaccine drug developed by Protein Sciences Corporation, indicated for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older.

How does Flublok Quadrivalent Influenza Vaccine work?

Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells.

What is Flublok Quadrivalent Influenza Vaccine used for?

Flublok Quadrivalent Influenza Vaccine is indicated for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years and older.

Who makes Flublok Quadrivalent Influenza Vaccine?

Flublok Quadrivalent Influenza Vaccine is developed by Protein Sciences Corporation (see full Protein Sciences Corporation pipeline at /company/protein-sciences-corporation).

What drug class is Flublok Quadrivalent Influenza Vaccine in?

Flublok Quadrivalent Influenza Vaccine belongs to the Recombinant protein vaccine class. See all Recombinant protein vaccine drugs at /class/recombinant-protein-vaccine.

What development phase is Flublok Quadrivalent Influenza Vaccine in?

Flublok Quadrivalent Influenza Vaccine is in Phase 3.

What are the side effects of Flublok Quadrivalent Influenza Vaccine?

Common side effects of Flublok Quadrivalent Influenza Vaccine include Injection site pain, Injection site erythema, Injection site swelling, Myalgia, Headache, Fatigue.

What does Flublok Quadrivalent Influenza Vaccine target?

Flublok Quadrivalent Influenza Vaccine targets Influenza hemagglutinin (HA) antigen and is a Recombinant protein vaccine.

Related